Diabetes Discourse

The EADS (Eating and Appraisal Due to Emotions and Stress) questionnaire developed by Dr. Amy Ozier, registered dietitian and certified health education specialist, and assistant professor and facilitator of the Certificate of Graduate Study for Eating Disorders and Obesity at Northern Illinois University, helps healthcare professionals determine how psychological and physical factors modulate how much patients with diabetes eat. Does this tool help to bridge the gap when a psychologist is missing from a multi-disciplinary team? Dr. Ozier joins host Dr. Steven Edelman to discuss overeating as a contributing factor in a patient's overall health, the impact of hyperglycemia and treatment that helps modulate behavior.

The potential benefits of a new class of medications, sodium-dependent glucose cotransporter-2 therapy (or SGLT-2s), for type 2 diabetes is promising, but where will they fit in the treatment of diabetes and what are the risks? Join host Dr. Steven Edelman and his guest, professor of medicine at the Veterans Affairs Medical Center in San Diego, California, Dr. Robert Henry, as they discuss the mechanism, benefits and potential cardiovascular risks of this new class of medication.

Healthcare reform will have significant implications for both patients living with diabetes and the healthcare professionals treating diabetic patients. How will healthcare reform impact current treatment, access and affordability? Join host Dr. Steven Edelman and his guest, executive vice president of government affairs & advocacy of the American Diabetes Association, Shereen Arent, as they discuss the impact of reform to cost of patient care, current and future prevention programs and the Affordable Care Act.

Patients with diabetes commonly need treatment for peripheral neuropathy. What are common symptoms and what should a physician be looking for in each patient visit? Join host Dr. Steven Edelman and his guest, practicing physician in the division of podiatric surgery at Kaiser Permanente, Dr. Craig Wargon, as they discuss symptoms, treatment and the need to glycaemic control in patients with diabetes.

The Centers for Disease Control and Prevention is aggressively becoming hands-on in the prevention of type 2 diabetes. A new national diabetes prevention program is under way under the tutelage of previous successful clinical research and trials results. What can healthcare professionals treating patients with diabetes learn and how can they get involved? Join host Dr. Steven Edelman and his guest, the director of the division of diabetes translation at the Centers for Disease Control and Prevention, Dr. Ann Albright, as they discuss the criteria for the National Diabetes Prevention Program.

Current stem cell therapy research is leading the way into producing functional pancreatic, insulin-producing cells. How will this translate into clinical trials and human therapy for diabetes from a scale, delivery and efficacy position? Join host Dr. Steven Edelman and his guest Dr. Emmanuel Baetge, chief scientific officer of Viacyte, Inc., as they discuss the benefits of stem cell research therapy for diabetes.

There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and his guest, medical director of the International Diabetes Center, Park Nicollet Health Services, Dr. Robert Cuddihy, as they discuss whether incretin-based therapy holds promise of a truly disease-modifying therapy.

What is known about the relationship between glucose control and cardiovascular disease in diabetes? The recent Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial provides some interesting results on the relationship between type 2 diabetes and silent myocardial infarction. Join host Dr. Steven Edelman and his guest, assistant professor of medicine in the division of endocrinology, metabolism and nutrition at Duke University, Dr. Jennifer Green, as they discuss the role of glycemic control to cardiovascular disease in both sexes.

The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illuminate this quandary? Join host Dr. Steven Edelman and his guest, chief scientific and medical officer of the American Diabetes Association, Dr. David Kendall, as they discuss the effect of glycemic control on macrovascular outcomes in patients with diabetes.

Guidelines that avoid the use of oral antidiabetes agents associated with hypoglycemia and weight gain are becoming increasingly popular in treating patients with diabetes. What are we learning about incretin-based therapies in both the intensive care and emergency medicine departments and perioperatively? Join host Dr. Steven Edelman and his guest, associate professor of medicine at the University of Pennsylvania, Dr. Stanley Schwartz, as they discuss the surprising results in both intensive care, emergency medicine and perioperative periods using incretin-based therapies.